GlassScriptPhysician profile
Lakshmi N Rajdev
NPI 1053491548
$35,761.00
in general payments reported to CMS, 2019-2025
20 companies · $3,628 in 2025
The $3,628 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,057 · 2020: $2,296 · 2021: $2,254 · 2022: $1,786 · 2023: $5,902 · 2024: $13K · 2025: $3,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $739 · Travel and Lodging: $112 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,449.00 |
| Food and Beverage | $738.93 |
| Travel and Lodging | $111.70 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $7,344.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,440.73 | 2019 | |
| Beigene USA, INC. | $5,094.03 | 2024 | Tevimbra |
| Amgen INC. | $3,430.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $3,315.64 | 2019-2025 | Imfinzi |
| Beone Medicines USA, INC. | $3,272.20 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $2,200.00 | 2023 | |
| Incyte Corporation | $2,155.00 | 2021 | |
| Daiichi Sankyo INC. | $1,712.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $407.89 | 2019-2023 | |
| Astellas Pharma US INC | $124.03 | 2023 | |
| Genentech, INC. | $52.94 | 2023 | |
| Merck Sharp & Dohme LLC | $51.85 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Exelixis INC. | $48.43 | 2025 | Cabometyx |
| Glaxosmithkline, LLC. | $29.00 | 2025 | Ojjaara |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $24.74 | 2025 | |
| Pfizer INC. | $23.95 | 2019 | |
| Genentech USA, INC. | $19.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmi Rajdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.